Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer

Table 1 Data about patients enrolled in this study

Characteristics	Patients, n (%)
Sex
Male	59 (65.6)
Female	31 (34.4)
Age (yr)
Median	53
Range	23-75
Tumor site
Colon	39 (43.3)
Rectal	51 (56.7)
Combined chemotherapy
Irinotecan-based	58 (64.4)
Oxaliplatin-based	29 (32.2)
Monotherapy	3 (3.3)
Cetuximab use
First line	29 (32.2)
Second line	23 (25.6)
Third line	28 (31.1)
Fourth line or more	10 (11.1)
Response status
Complete response	3 (3.3)
Partial response	31 (34.4)
Stable disease	35 (38.9)
Progressive disease	21 (23.3)

Table 2 Correlation of KRAS gene status and phosphatase and tensin protein expression with clinical response to cetuximab in previously treated colorectal cancer patients n (%)

	KRAS			PTEN
	Mutation	No mutation	P	Positive	Negative	P
CR	0 (0)	2 (5.1)	0.001	2 (5.4)	0 (0)	0.001
PR	1 (4.5)	16 (41.0)		16 (43.2)	1 (4.2)
SD	7 (31.8)	17 (43.6)		10 (27.0)	14 (58.3)
PD	14 (63.6)	4 (10.3)		9 (24.3)	9 (37.5)
Total	22 (100)	39 (100)		37 (100)	24 (100)